# A Xenopus Laevis Research Resource for Immunobiology

> **NIH NIH R24** · UNIVERSITY OF ROCHESTER · 2024 · $432,270

## Abstract

The goal of this renewal application is to maintain and further develop the world's most comprehensive
research resource specializing in the use of the amphibian Xenopus laevis as a multi-faceted
experimental platform for biomedical and immunological research and for the benefit of the whole
scientific community. Interests and medical relevance of X. laevis are due to the remarkable similarity of its
immune system with that of human, the accessibility to experimentation at all developmental stages, as well as
the availability of large genetic and genomic resources, invaluable MHC-defined inbred strains, clones and
transgenic (Tg) lines of frogs, as well as tools such as cell lines, monoclonal antibodies, MHC tetramers,
tagged recombinant reagents and batteries of validated PCR primers for immune-relevant genes. These
animals and reagents that are not commercially available need to be preserved, enriched, and made available
to the scientific community. As in previous proposals, two major main aims are proposed:
(1)
Preserving and promoting the X. laevis research resource for immunobiology
by keeping on
producing, managing and distributing animal stocks and reagents to laboratories in the US and abroad. We will
maintain the quality, productivity and welfare of our inbred and Tg animals. We will assist, train and inform
scientists, students and educators interested in using X. laevis for research. We will foster the information,
accessibility, networking and public awareness of the resource using our web site, and by interacting with other
Xenopus resources nationally and internationally.
(2)
Developing new methodologies and generating new experimental animals and reagents
by
leveraging X. laevis to advance research in 3 main areas: (1) Genetically modified X. laevis lines of frogs: to
improve genome annotation, generate new CRISPR/Cas9-mediated inbred Tg knockout (KO) lines and lines
with traceable immune cell types by knocking-in long single stranded donor templates (lssDNA). (2) X. laevis
cell culture systems and reagents: to produce transfected and deficient cell lines, recombinant tagged immune
reagents and MHC tetramers as well as to develop VSV-lentiviral transducing vectors for in vitro and in vivo
studies in Xenopus. (3) X. laevis experimental platforms for infectious disease and developmental
immunotoxicology: to develop cost-effective and reliable experimental platforms to study infection and
pathogenicity of emerging human non-tuberculosis mycobacterium (NTM) pathogens (e.g., M. abscessus); and
assess overlooked risk for immunity and human health of water pollutants with endocrine disruption activity. In
addition to maintaining a research resource that is crucial for the Xenopus scientific community, this project will
develop new approaches and technologies broadly applicable for gathering innovative insights into tissue and
organ physiology, immunology and developmental biology. This will contribute to the efforts of the scientific
comm...

## Key facts

- **NIH application ID:** 10905983
- **Project number:** 5R24AI059830-21
- **Recipient organization:** UNIVERSITY OF ROCHESTER
- **Principal Investigator:** JACQUES Robert
- **Activity code:** R24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $432,270
- **Award type:** 5
- **Project period:** 2004-06-01 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10905983

## Citation

> US National Institutes of Health, RePORTER application 10905983, A Xenopus Laevis Research Resource for Immunobiology (5R24AI059830-21). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10905983. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*